The CD133 antigen, a penta-span transmembrane glycoprotein, is a potential target for CAR T-cell therapy, being overexpressed in pancreatic and colorectal cancer and hepatocellular carcinoma, amongst others. This evidence concerns the gene PROM1 and colorectal cancer.